Novartis wins FDA Okay, Sanofi Subsidiary Wins in Oz: Healthcare Business Update

On Tuesday, the FDA okayed Flucelvax, made by Novartis (NYSE:NVS), which is the first seasonal influenza vaccine made without fertilized chicken eggs. Rather, the med is produced using cultured animal cells; this tech has been utilized for other types of vaccines over several decades.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Reckitt Benckiser Group (RBGPF.PK) has signed a definitive merger agreement Wednesday with Schiff Nutrition International (SHF), in a transaction that values the latter at $1.4 billion. Schiff’s board recommends that shareholders tender their shares at the cash offer of $42.

An announcement by the Sanofi-Aventis (NYSE:SNY) division Genzyme, said that the Therapeutic Goods Administration in Australia has okayed Aubagio (teriflunomide) 14 mg for use as a new once-daily, oral treatment indicated for patients suffering from relapsing forms of multiple sclerosis. This approval will permit health professionals to prescribe Aubagio 14 mg in Australia, which now represents the second nation to gain marketing authorization for the treatment, following the FDA approval back in September.

Don’t Miss: Are Patent-Holding Companies Holding Innovation Hostage?